Publication
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMalignant Ovarian Neoplasmcivic_curation1.00
- drugRucaparibcivic_curation1.00
- geneBRCA1civic_curation1.00
- geneBRCA2civic_curation1.00
- variantBRCA1 Mutationcivic_curation1.00
- variantBRCA2 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28882436
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRCA1 Mutation2 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11136Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11138Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC | civic |
| BRCA2 Mutation2 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11137Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11139Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC | civic |
| BRCA1 Mutation + BRCA2 MutationBRCA2BRCA11 | ||||||||
| Rucaparib | Fallopian Tube, Ovarian Cancer, And Peritoneal Serous CarcinomaUNRESOLVED | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11246In an integrated analysis of Study 10 (NCT01482715) and ARIEL2 (NCT01891344) trials, 106 patients with either germline or somatic BRCA1 or BRCA2 who received a starting dose of oral rucaparib 600mg tw… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC | civic |